SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape
- PMID: 35120605
- PMCID: PMC8758318
- DOI: 10.1016/j.chom.2022.01.005
SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape
Abstract
Characterizing SARS-CoV-2 evolution in specific geographies may help predict properties of the variants that come from these regions. We mapped neutralization of a SARS-CoV-2 strain that evolved over 6 months from ancestral virus in a person with advanced HIV disease in South Africa; this person was infected prior to emergence of the Beta and Delta variants. We longitudinally tracked the evolved virus and tested it against self-plasma and convalescent plasma from ancestral, Beta, and Delta infections. Early virus was similar to ancestral, but it evolved a multitude of mutations found in Omicron and other variants. It showed substantial but incomplete Pfizer BNT162b2 escape, weak neutralization by self-plasma, and despite pre-dating Delta, it also showed extensive escape of Delta infection-elicited neutralization. This example is consistent with the notion that SARS-CoV-2 evolving in individual immune-compromised hosts, including those with advanced HIV disease, may gain immune escape of vaccines and enhanced escape of Delta immunity, and this has implications for vaccine breakthrough and reinfections.
Keywords: Beta variant; Delta variant; HIV; SARS-CoV-2; advanced HIV disease; evolution; immune escape; neutralization; variants of concern.
Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests The authors declare no competing interests.
Figures



Update of
-
SARS-CoV-2 evolved during advanced HIV disease immunosuppression has Beta-like escape of vaccine and Delta infection elicited immunity.medRxiv [Preprint]. 2021 Dec 7:2021.09.14.21263564. doi: 10.1101/2021.09.14.21263564. medRxiv. 2021. Update in: Cell Host Microbe. 2022 Feb 9;30(2):154-162.e5. doi: 10.1016/j.chom.2022.01.005. PMID: 34909798 Free PMC article. Updated. Preprint.
References
-
- Acevedo M.L., Alonso-Palomares L., Bustamante A., Gaggero A., Paredes F., Cortés C.P., Valiente-Echeverría F., Soto-Rifo R. Infectivity and immune escape of the new SARS-CoV-2 variant of interest Lambda. medRxiv. 2021 2021.06.28.21259673.
-
- Andrews N., Stowe J., Kirsebom F., Toffa S., Rickeard T., Gallagher E., Gower C., Kall M., Groves N., O’Connell A.-M., et al. Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern. medRxiv. 2021 2021.12.14.21267615.
-
- Avelino-Silva V.I., Miyaji K.T., Mathias A., Costa D.A., de Carvalho Dias J.Z., Lima S.B., Simoes M., Freire M.S., Caiaffa-Filho H.H., Hong M.A., et al. CD4/CD8 ratio predicts yellow fever vaccine-induced antibody titers in virologically suppressed HIV-infected patients. J. Acquir. Immune Defic. Syndr. 2016;71:189–195. - PubMed
Publication types
MeSH terms
Substances
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous